Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497617 | 0.79 | CA12 (0.36) | ALDH1A1TDP1TSHR | |
| SCHEMBL15471176 | 0.79 | CHRM2 (0.36) | CHRM1ALDH1A1CHRM2CHRM4CHRM5 | |
| SCHEMBL968380 | 0.78 | SLC6A2 (0.33) | SLC6A2 | |
| SCHEMBL968381 | 0.78 | MEN1 (0.37) | CHRM1ALDH1A1SLC6A2TSHR | |
| SCHEMBL23590364 | 0.76 | ALDH1A1 (0.30) | ALDH1A1TSHR | |
| SCHEMBL22704214 | 0.76 | GRM5 (0.32) | SLC6A2 | |
| SCHEMBL8599594 | 0.76 | TSHR (0.36) | ALDH1A1SLC6A2TSHR | |
| SCHEMBL969639 | 0.76 | SLC6A2 (0.32) | SLC6A2 | |
| SCHEMBL8403036 | 0.76 | LMNA (0.33) | ALDH1A1TDP1SLC6A2TSHR | |
| SCHEMBL12245562 | 0.76 | MEN1 (0.33) | SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190125701-A1 | Compositions and Methods for Treating Viral Infection in Mammals | UNIV YALE (US) | 2019-05-02 | — | — | US | claimed |
| EP-3452172-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION IN MAMMALS | Yale University (US) | 2019-03-13 | — | — | EP | claimed |
| WO-2017192799-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION IN MAMMALS | YALE UNIVERSITY (US) | 2017-11-09 | — | — | WO | claimed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-11 | — | — | US | disclosed |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-10-29 | — | — | US | disclosed |
| US-20190125701-A1 | Compositions and Methods for Treating Viral Infection in Mammals | UNIV YALE (US) | 2019-05-02 | — | — | US | disclosed |
| EP-3452172-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION IN MAMMALS | Yale University (US) | 2019-03-13 | — | — | EP | disclosed |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-02-14 | — | — | US | disclosed |
| WO-2017192799-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION IN MAMMALS | YALE UNIVERSITY (US) | 2017-11-09 | — | — | WO | disclosed |
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-02-09 | — | — | US | disclosed |
| EP-2157084-A1 | 5-PHENYL-3-PYRIDAZINONE DERIVATIVE | Kowa Company, Ltd. (JP) | 2010-02-24 | — | — | EP | disclosed |
| US-20080051423-A1 | NITROGEN HETEROCYCLE BIARYLS FOR OSTEOPOROSIS AND OTHER DISEASES | PHARMACOPEIA, INC. (US) | 2008-02-28 | — | — | US | disclosed |
| US-20070213315-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-13 | — | — | US | disclosed |
| EP-0958292-B1 | 4-(3-HETEROCYCLYL-1-BENZOYL)PYRAZOLES AND THEIR USE AS HERBICIDES | BASF AG (DE) | 2007-01-03 | — | — | EP | disclosed |
| US-6165944-A | 4-(3-heterocyclyl-1-benzoyl) pyrazoles and their use as herbicides | BASF AKTIENGESELLSCHAFT (DE) | 2000-12-26 | — | — | US | disclosed |
| EP-0777658-B1 | SUBSTITUTED TRIAZOLINONES AS PLANT PROTECTIVE AGENTS | BASF AG (DE) | 1999-12-15 | — | — | EP | disclosed |
| EP-0958292-A1 | 4-(3-HETEROCYCLYL-1-BENZOYL)PYRAZOLES AND THEIR USE AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1999-11-24 | — | — | EP | disclosed |
| US-5885934-A | HERBICIDES OR FOR THE DESICCATION/DEFOLIATION OF PLANTS | BASF AKTIENGESELLSCHAFT (DE) | 1999-03-23 | — | — | US | disclosed |
| WO-1998031682-A1 | 4-(3-HETEROCYCLYL-1-BENZOYL)PYRAZOLES AND THEIR USE AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1998-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213315-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | CHRM1 6/4885ALDH1A1 2356/4885CHRM2 3/4885 |
| US-20080051423-A1 | NITROGEN HETEROCYCLE BIARYLS FOR OSTEOPOROSIS AND OTHER DISEASES | EDNRA, EDNRB, ESRRB | CHRM1 2499/4885ALDH1A1 820/4885CHRM2 1608/4885 |
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | ERBB2, EGFR, LANCL2 | CHRM1 1240/4885ALDH1A1 2238/4885CHRM2 1625/4885 |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | CHRM1 227/4885ALDH1A1 1598/4885CHRM2 691/4885 |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | CHRM1 227/4885ALDH1A1 1598/4885CHRM2 691/4885 |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | CHRM1 209/4885ALDH1A1 1601/4885CHRM2 651/4885 |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | CHRM1 227/4885ALDH1A1 1598/4885CHRM2 691/4885 |
| US-20190125701-A1 | Compositions and Methods for Treating Viral Infection in Mammals | RPL35, PIGS, HAVCR2 | CHRM1 4453/4885ALDH1A1 3379/4885CHRM2 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.